Shares of Arcus Biosciences Inc (NYSE:RCUS) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $16.56.
A number of analysts have recently commented on RCUS shares. ValuEngine upgraded Arcus Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Svb Leerink reiterated an “outperform” rating on shares of Arcus Biosciences in a research report on Friday, May 3rd. Citigroup cut their target price on Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a research report on Wednesday, June 5th. Finally, Zacks Investment Research upgraded Arcus Biosciences from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a research report on Thursday, July 4th.
In related news, President Juan C. Jaen purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average price of $7.59 per share, for a total transaction of $113,850.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kathryn E. Falberg purchased 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was bought at an average price of $8.20 per share, for a total transaction of $164,000.00. The disclosure for this purchase can be found here. Insiders have bought 140,343 shares of company stock worth $1,120,078 in the last quarter. Insiders own 19.23% of the company’s stock.
Shares of RCUS traded up $0.01 during midday trading on Thursday, reaching $6.60. 2,777 shares of the stock were exchanged, compared to its average volume of 96,264. The firm has a 50-day simple moving average of $8.34. Arcus Biosciences has a twelve month low of $6.30 and a twelve month high of $16.06. The stock has a market cap of $304.62 million, a P/E ratio of -4.57 and a beta of 1.02.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.